Building Bridges: The Impact of Medical Science Liaison and Advanced Practice Provider Collaborations - Top-Institutions - MDSpire

Building Bridges: The Impact of Medical Science Liaison and Advanced Practice Provider Collaborations

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    University of Oklahoma Health Sciences
    University of Oklahoma Health Sciences

    Oklahoma City, OK

    Key Differentiators

    • Pharmacy

  • #2

    OU Health–Stephenson Cancer Center
    OU Health–Stephenson Cancer Center

    Oklahoma City, OK

    Key Differentiators

    • Pharmacy

  • #3

    Fox Chase Cancer Center
    Fox Chase Cancer Center

    Philadelphia, PA

    Key Differentiators

    • Pharmacy

  • #4

    University of Colorado Anschutz Medical Campus
    University of Colorado Anschutz Medical Campus

    Aurora, CO

    Key Differentiators

    • Pharmacy

  • #5

    National Comprehensive Cancer Network (NCCN)
    National Comprehensive Cancer Network (NCCN)

    Fort Washington, PA

    Key Differentiators

    • Pharmacy

Original Source(s)

Building Bridges: The Impact of Medical Science Liaison and Advanced Practice Provider Collaborations

  • by Katherine Albert, Kristina Byers, Chelsey Boggs

  • May 6, 2026

Related Content

This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar

Plus: NICE backs rozanolixizumab for uncontrolled gMG, Genexine reports SOX2 degrader data, and BeOne secures option on Huahui trispecific antibody

  • May 5, 2026

  • 5 min
COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

Zoldonrasib in Patients With <em>KRAS</em> G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy

The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were pr...